CytomX Therapeutics announced the appointment of Zhen Su, M.D., M.B.A. to the company’s board of directors. Su is an accomplished physician executive with nearly three decades of experience leading oncology research and development and commercial organizations. Dr. Su is currently chief executive officer of Marengo Therapeutics
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CTMX:
- CytomX Therapeutics announces milestone achievement in PROBODY TCB
- CytomX Therapeutics Braces for Increased Compliance Costs as it Outgrows ‘Smaller Company’ Status
- CytomX Therapeutics price target lowered to $3.25 from $3.30 at BMO Capital
- CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update
- Options Volatility and Implied Earnings Moves Today, March 11, 2024
